Address
4149 Liberty Canyon Road
Agoura Hills, CA 91301
United States of America (the)
Phone
805-730-0360
Website
Sector
Healthcare
Industry
Biotechnology
Employees
83
First IPO Date
May 04, 2023
| Name | Title | Pay | Year Born |
| Mina Kim | Chief Executive Officer & Director | 906,640 | 1974 |
| Shephard Mpofu | Chief Medical Officer | 679,645 | 1967 |
| K. Amar Murugan | Chief Legal Officer | 0 | 1976 |
| Kenneth A. Lock | Chief Commercial Officer | 0 | 1974 |
| Tyler Marciniak | Vice President of Investor Relations, Communications & Corporate Operations | 0 | N/A |
| Kelly Chow | Chief People Officer | 0 | N/A |
| Patricia A. Turney | Chief Technical Operations Officer | 0 | 1967 |
Acelyrin, Inc. is a biopharmaceutical company focused on discovering, obtaining, and rapidly advancing the development and commercialization of innovative medical therapies. The firm's most advanced experimental drug is izokibep, a potent small protein therapeutic specifically designed to block IL-17A. This compound is currently undergoing Phase 3 clinical evaluations for its use in treating Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis. Additionally, izokibep is being assessed in Phase 2 clinical trials for Axial Spondyloarthritis. Beyond izokibep, Acelyrin is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets the insulin-like growth factor 1 receptor. Lonigutamab is in Phase 1 clinical studies for individuals with thyroid eye disease. Furthermore, the company has SLRN-517, a fully human IgG1 monoclonal antibody aimed at c-KIT, which is in the preclinical stage of development for the treatment of chronic urticaria. Founded in 2020, Acelyrin's corporate headquarters are located in Agoura Hills, California.